Marlana Orloff, MD
Medical Oncology · Philadelphia, PANPI 1750515078
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Immunocore Limited accounts for 62.6% of it on its own, with 6 other manufacturers making up the rest.
Across 81 payments — averaging $635.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Immunocore Limited$32K
- E.r. Squibb & Sons, L.L.C.$8K
- Delcath Systems$7K
- Trisalus Life Sciences, Inc.$4K
- Iovance Biotherapeutics, Inc.$274
- Galvanize Therapeutics, Inc$172
- plus $90 from 1 others
Across 70 payments — averaging $26,753 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Trisalus Life Sciences, Inc.$260K
- Iovance Biotherapeutics, Inc.$70K
- E.r. Squibb & Sons, L.L.C.$68K
- Immunocore Limited$64K
- Seagen Inc.$30K
- plus $25K from 1 others
What the payments were for
- Consulting fees$28,52755%
- Speaking & faculty fees$12,50024%
- Travel & lodging$8,08516%
- Food & beverage$2,3235%
- Gifts$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Immunocore Limited | 47 | $32,195 |
| E.r. Squibb & Sons, L.L.C. | 5 | $7,656 |
| Delcath Systems | 9 | $7,360 |
| Trisalus Life Sciences, Inc. | 14 | $3,716 |
| Iovance Biotherapeutics, Inc. | 2 | $274 |
| Galvanize Therapeutics, Inc | 1 | $172 |
| Regeneron Healthcare Solutions, Inc. | 3 | $90 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KIMMTRAK$31,861
- Hepzato Kit$7,217
- TRINAV INFUSION SYSTEM$3,310
- Amtagvi$274
- ALIYA SYSTEM$172
How this compares
$51,464 in reported general payments places this provider in the 85th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Philadelphia
- Carl JunePhiladelphia$9M
- Shayma KazmiPhiladelphia$619K
- Marcia BrosePhiladelphia$260K
- Adam CohenPhiladelphia$239K
- Daniel HallerPhiladelphia$227K
- Edith MitchellPhiladelphia$220K
- Elizabeth PlimackPhiladelphia$190K
- Alexander PerlPhiladelphia$176K
- Martin EdelmanPhiladelphia$157K
- Jean-Pierre IssaPhiladelphia$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.